Table 4.
Surgical exploration and resection rates after neoadjuvant therapy
| Surgical treatment | Explored/N | Resected/N | R0/N | Resected/explored | R0/resected |
|---|---|---|---|---|---|
| Resectable | 86% | 76% | 63% | 92% | 88% |
| [79–92%] | [68–84%] | [51–75%] | [85–97%] | [80–94%] | |
| I 2 = 83.91% | I 2 = 86.02% | I 2 = 90.69% | I 2 = 83.37% | I 2 = 81.82% | |
| (n = 18) | (n = 18) | (n = 14) | (n = 18) | (n = 14) | |
| Borderline resectable | 77% | 69% | 54% | 91% | 84% |
| [66–86%] | [59–78%] | [37–71%] | [84–96%] | [67–96%] | |
| I 2 = 87.62% | I 2 = 88.98% | I 2 = 95.15% | I 2 = 70.68% | I 2 = 93.75% | |
| (n = 15) | (n = 18) | (n = 16) | (n = 15) | (n = 16) | |
| Locally advanced | 32% | 26% | 23% | 86% | 82% |
| [23–42%] | [19–34%] | [15–33%] | [73–95%] | [69–93%] | |
| I 2 = 91.44% | I 2 = 89.42% | I 2 = 91.18% | I 2 = 86.04% | I 2 = 82.75% | |
| (n = 22) | (n = 24) | (n = 18) | (n = 19) | (n = 15) | |
| BR + LA | 65% | 53% | 39% | 89% | 85% |
| [49–79%] | [36–70%] | [27–52%] | [80–96%] | [79–90%] | |
| I 2 = 95.67% | I 2 = 96.04% | I 2 = 92.74% | I 2 = 85.80% | I 2 = 35.55% | |
| (n = 20) | (n = 22) | (n = 20) | (n = 19) | (n = 19) | |
| All patients | 64% | 55% | 45% | 91% | 85% |
| [57% -71%] | [48–62%] | [38–52%] | [87–94%] | [80–89%] | |
| I 2 = 95.27% | I 2 = 95.34% | I 2 = 94.94% | I 2 = 84.53% | I 2 = 85.05% | |
| (n = 84) | (n = 90) | (n = 74) | (n = 79) | (n = 70) |
Values in [] reflect the 95% confidence interval. I 2 is a quantitative indicator of heterogeneity among the studies, n refers to the number of studies reporting the outcomes